Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
With
United States Department of Defense
This is an explorative diagnostic basic research study to assess the value of 18F-choline PET/CT and multi-sequence MRI for prostate cancer in patients undergoing diagnostic prostate biopsy. Patients will receive image-guided (targeted) prostate biopsies and metabolomic profiling of prostate biopsy tissues to evaluate underlying metabolic changes in comparison with pathological Gleason grading.
Age
40–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Males 40 years of age or older scheduled for prostate biopsy (for known or suspected prostate cancer) followed by planned prostatectomy (population group A)
Males 40 years of age or older with known (biopsy-confirmed) primary adenocarcinoma of the prostate undergoing active surveillance scheduled for prostate biopsy (population group B)
You may not be if
Androgen ablation (hormone treatment) within the last 3 months
Prostate biopsy within 6 weeks prior to PET or MRI imaging
Active inflammatory bowel disease within the last 6 months
Acute prostatitis within the last 6 months
A non-urologic bacterial infection requiring active treatment with antibiotics
Active other malignancy (except basal cell or squamous cell skin cancer) within the last 2 years
Previous radiation treatment of the pelvis
Symptomatic distal rectal stenosis
Known hypersensitivity to glucagon
Pheochromocytoma, insulinoma or galactosemia
Insulin-dependent diabetes
Clareo Health | Choline PET/CT and MRI for Targeted Prostate Biopsy
